LOPRESOR 100MG TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

METOPROLOL TARTRATE

제공처:

NOVARTIS PHARMACEUTICALS CANADA INC

ATC 코드:

C07AB02

INN (국제 이름):

METOPROLOL

복용량:

100MG

약제 형태:

TABLET

구성:

METOPROLOL TARTRATE 100MG

관리 경로:

ORAL

패키지 단위:

100

처방전 유형:

Prescription

치료 영역:

BETA-ADRENERGIC BLOCKING AGENTS

제품 요약:

Active ingredient group (AIG) number: 0111923003; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2019-10-22

제품 특성 요약

_ _
_ _
_Page 1 of 42_
PRODUCT MONOGRAPH
PR
LOPRESOR
®
(metoprolol tartrate)
50 mg and 100 mg tablets
100 mg and 200 mg slow-release tablets
5 mL ampoules (1 mg/mL)
β-Adrenergic Receptor Blocking Agent
Novartis Pharmaceuticals Canada Inc.
385 Bouchard boulevard
Dorval, Quebec
H9S 1A9
Date of Preparation:
June 21, 1977
Date of Revision:
April 14, 2020
Submission Control No: 235180
LOPRESOR and LOPRESOR SR are Registered Trademarks
_ _
_ _
_Page 2 of 42_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................19
OVERDOSAGE
................................................................................................................22
ACTION AND CLINICAL PHARMACOLOGY
............................................................23
STORAGE AND STABILITY
..........................................................................................26
SPECIAL HANDLING INSTRUCTIONS
.......................................................................26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................27
PART II: SCIENTIFIC INFORMATION
...............................................................................28
PHARMACEUTICAL INFORMATION
..................